ch.oddb.org
 
Apotheken | Hôpital | Interactions | LiMA | Médecin | Médicaments | Services | T. de l'Autorisation
Information professionnelle sur Seebri® Breezhaler®:Novartis Pharma Schweiz AG
Information professionnelle complèteDDDAfficher les changementsimprimé 
Composit.Forme gal.Indic./emploiPosolog./mode d'empl.Contre-Ind.PrécautionsInteract.Grossesse
Apt.conduiteEffets indésir.SurdosagePropriétésPharm.cinét.Donn.précl.RemarquesNum. Swissmedic
PrésentationsTitulaireMise à jour 
R03BB06 - Glycopyrronium BromideATC-DDD Version 2016. Source: WHO
R - Respiratory System

Inhaled antiinfectives are classified in ATC group J - Antiinfectives for systemic use.

R03 - Drugs for Obstructive Airway Diseases
 
R03B - Other Drugs for Obstructive Airway Diseases, Inhalants

This group comprises all drugs for obstructive airway diseases for inhalation excl. adrenergics (R03A).

See comment under R03A.

R03BB - Anticholinergics

Combinations with adrenergics are classified in R03AL.
The combination of tiotropium bromide and ciclosonide is classified in R03BB54.

The DDDs are based on the maintenance treatment of asthma.
The DDDs for tiotropium bromide and umeclidinium bromide are based on treatment of COPD (Chronic Obstructive Pulmonary Disease).
The DDD for tiotropium bromide inhalation powder is based on tiotropium, delivered dose.
The DDD for aclidinium bromide inhalation powder is based on aclidinium, delivered dose.
The DDD for glycopyrronium bromide inhalation powder is based on glycopyrronium, delivered dose.
The DDD for umeclidinium bromide inhalation powder is based on umeclidinium, delivered dose.

R03BB06 - Glycopyrronium Bromide
Concentr.Adm.RouteNote
   
2024 ©ywesee GmbH
Einstellungen | Aide | FAQ | Identification | Contact | Home